Observational Study of Molecular Residual Disease Using Circulating Tumor DNA in Stage I-III Colon Adenocarcinoma with Driver Mutations
Led by Ruijin Hospital · Updated on 2026-09-02
392
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of circulating tumor DNA ctDNA testing to monitor molecular residual disease MRD in patients with stage I-III colon adenocarcinoma who have specific driver mutations KRAS, NRAS, BRAF, or PIK3CA and have undergone surgery to remove their tumors. This observational study aims to understand how MRD status after surgery relates to the risk of cancer recurrence and survival outcomes. The study fills a gap by focusing on patients with these genetic mutations and following them closely over time.
Participants will have blood samples taken at set times before and after surgery, including several points during a three-year follow-up period. These samples will be tested using a specialized 10-gene sequencing panel to detect tumor DNA fragments in the blood, which may indicate residual cancer. No experimental treatments are given all patients receive standard care and monitoring according to clinical guidelines.
During the study, participants will undergo regular physical exams, blood tests for tumor markers, CT scans every six months, and colonoscopies at specified intervals up to three years after surgery. Researchers will analyze how ctDNA results correspond with cancer recurrence and overall survival. The study includes careful tracking of changes in MRD over time and their relationship with outcomes after any additional chemotherapy. The total follow-up lasts three years post-surgery.
CONDITIONS
Brief Title
Postoperative Circulating Tumor DNA Monitoring in Stage I-III Driver-Mutant Colon Adenocarcinoma
Research Team
R
Ren Zhao, MD, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Pathologically confirmed stage I-III colon adenocarcinoma without prior endoscopic submucosal dissection or mucosal resection
Planned curative surgery without previous anti-tumor therapy
Eastern Cooperative Oncology Group performance status of 0 or 1
Presence of at least one driver mutation (KRAS, NRAS, BRAF, or PIK3CA) in tumor tissue
Voluntary consent with good compliance to follow-up and blood sampling
You will not qualify if you...
Received neoadjuvant chemotherapy, radiotherapy, or targeted therapy before surgery
History of other malignant tumors excluding non-adenomatous colorectal neoplasms
Pregnant or breastfeeding women
Severe systemic diseases interfering with follow-up or survival
Abnormal lab values or social/family issues affecting sample collection or follow-up
Participation in other interventional trials requiring assigned postoperative treatment
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are evaluated for eligibility based on medical history and tumor characteristics.
1 visit (in-person)
Postoperative Blood Sampling and Monitoring
Duration - 3 years
Participants have blood drawn at multiple scheduled times to test for circulating tumor DNA indicating residual disease. Standard clinical follow-up with physical exams and tumor marker tests occurs alongside imaging and colonoscopy as per guidelines.
Blood draws at baseline, day 7 ±2 post-surgery, 1 month post-surgery, then every 3 months up to 12 months, every 6 months up to 36 months; CT scans every 6 months; colonoscopy at 12, 24, and 36 months
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Evaluating Calderasib Combined With Cetuximab and mFOLFOX6 Compared to mFOLFOX6 With or Without Bevacizumab for KRAS G12C-Mutant Advanced or Metastatic Colorectal Cancer
Evaluating Chemotherapy Based on Circulating Tumor DNA in Colon Cancer After Surgery
A Randomized Study Comparing Treatment Options for Patients With Resected Stage II and III Colon Cancer
Retrospective Study of First-Line Chemotherapy with Monoclonal Antibodies in Patients 70 to 99 Years Old with Metastatic Colorectal Adenocarcinoma
Testing PreveCol Blood Test as a Second Step for Early Detection
of Colorectal Cancer in Adults Aged 50 to 69 with Positive FOBT Results
Comparing Patient- and Provider-Led Communication for Genetic Testing in Relatives of Newly Diagnosed Colorectal Cancer Patients
Assessment of Minimal Residual Disease Using Liquid Biopsies in Stage III Colorectal Cancer Patients The French FRENCH.MRD.CRC Study as Part of the GUIDE.MRD Consortium
Study of HDAC Inhibitors Combined With Immunochemotherapy Versus Chemotherapy Alone in Treating Adults With Locally Advanced Colon Cancer
Living Donor Liver Transplant for Unresectable Colorectal Cancer Liver Metastases
The LIVERMORE Trial at Modena
Observation of Residual Cancer Using Guardant Reveal Blood Test
Tracking Cancer Recurrence in Early-Stage Solid Tumors
An Observational Study by Guardant Health
Phase II Study of Neoadjuvant Atezolizumab with CAPOX Chemotherapy Followed by Surgery for Resectable Non-metastatic pMMR Colon Cancer